Loading…
Elicio Therapeutics, Inc. is projected to rise to $4.12 by 2027, a +47% move from its current price of $2.80. ELTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.61 | $2.80 | $3.00 | +0.02% |
| Aug 6 | $2.54 | $2.80 | $3.09 | +0.03% |
| Aug 7 | $2.48 | $2.80 | $3.16 | +0.05% |
| Aug 8 | $2.43 | $2.80 | $3.22 | +0.06% |
| Aug 9 | $2.40 | $2.80 | $3.28 | +0.08% |
| Aug 10 | $2.36 | $2.80 | $3.33 | +0.09% |
| Aug 11 | $2.33 | $2.80 | $3.38 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.33 | $2.80 | $3.38 | +0.11% |
| Week 2 | $2.16 | $2.81 | $3.65 | +0.22% |
| Week 3 | $2.04 | $2.81 | $3.87 | +0.33% |
| Week 4 | $1.94 | $2.81 | $4.08 | +0.44% |
| Week 5 | $1.86 | $2.82 | $4.26 | +0.55% |
| Week 6 | $1.79 | $2.82 | $4.44 | +0.66% |
| Week 7 | $1.73 | $2.82 | $4.61 | +0.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted AMP peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant BRAF driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics is headquartered in Boston, Massachusetts. At the market level, the stock ELTX trades within the Healthcare sector.
The stock ELTX is associated with a current price of $2.80 and a market capitalization of $73.54M. The asset carries a rank of 4306.
Overall, the description reflects a clinical-stage biotechnology company focused on cancer immunotherapies with multiple AMP peptide programs in different stages of development.
ELTX is the stock ticker for Elicio Therapeutics, Inc., a Healthcare sector biotechnology company. It is currently priced at $2.80 per share and has a market capitalization of $73.54M, ranking 4306.
The price outlook based on the year-by-year forecast shows the average price rising over time, starting at $2.80 in 2026 and moving through multiple milestones: 2027 $4.13, 2028 $4.10, 2029 $4.05, 2030 $4.09, 2031 $3.98, 2032 $5.13, 2033 $6.53, 2034 $7.21, 2035 $7.57, 2040 $12.68, and 2050 $14.76.
Forecasted returns (ROI) follow a similar upward trajectory: 2026 0%, 2027 47.4%, 2028 46.5%, 2029 44.6%, 2030 46.1%, 2031 42.2%, 2032 83.2%, 2033 133.1%, 2034 157.7%, 2035 170.4%, 2040 352.8%, and 2050 427.2%. The sentiment accompanying the longer horizon is BULLISH for the majority of years after 2026.
A major floor 55.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 83.6% above — a clean break opens room to run.
A major ceiling 430.4% above — clearing it would confirm fresh momentum.
Key ELTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ELTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.91 | Sell | $2.90 | Sell |
| MA 10 | $2.99 | Sell | $3.00 | Sell |
| MA 20 | $3.11 | Sell | $3.48 | Sell |
| MA 50 | $6.41 | Sell | $5.52 | Sell |
| MA 100 | $8.74 | Sell | $7.27 | Sell |
| MA 200 | $8.83 | Sell | $8.21 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.29 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -128.74 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.21 | Buy |
| ROC (12) | -7.89 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -3.09 | Sell |
| Awesome (5,34) | -0.88 | Sell |
| Ultimate (7,14,28) | 20.20 | Buy |
| Momentum (10) | -0.31 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 2.83 | Sell |
| ADX (14) | 28.76 | Sell |
| ATR (14) | 0.29 | Info |
The 30-day technical picture is NEUTRAL. The RSI(14) sits at 30, and the 50-day and 200-day simple moving averages are $6.41 and $8.83 respectively. Immediate support is at $2.80 and resistance at $5.14. The 30-day range spans $1.76 to $4.45, and the annualized volatility is 100%.
This setup suggests a cautious near-term stance, with a possible range-bound motion around the current level before any longer-term move toward the higher forecasted averages materializes.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.76 | $2.80 | $3.58 | 0% | Neutral | |
| $3.00 | $4.12 | $6.11 | +47% | Bullish | |
| $2.82 | $4.11 | $6.51 | +47% | Bullish | |
| $2.63 | $4.05 | $6.73 | +45% | Bullish | |
| $2.53 | $4.08 | $7.06 | +46% | Bullish | |
| $2.37 | $3.99 | $7.16 | +43% | Bullish | |
| $2.91 | $5.13 | $9.48 | +83% | Bullish | |
| $3.56 | $6.51 | $12.38 | +133% | Bullish | |
| $3.79 | $7.23 | $14.09 | +158% | Bullish | |
| $3.82 | $7.56 | $15.08 | +170% | Bullish | |
| $5.72 | $12.70 | $27.86 | +354% | Bullish | |
| $6.63 | $14.74 | $33.90 | +426% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.76 | $2.80 | $3.29 | +0.00% |
| September 2026 | $2.22 | $2.70 | $3.43 | -3.42% |
| October 2026 | $2.30 | $2.84 | $3.68 | +5.03% |
| November 2026 | $2.20 | $2.74 | $3.61 | -3.43% |
| December 2026 | $2.13 | $2.68 | $3.58 | -2.27% |
Click any year to see its month-by-month ELTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Elicio Therapeutics, Inc.'s 2026 outlook centres on $2.80, within a $2.76 to $3.58 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ELTX could reach as high as $6.11, with a base case around $4.12 and support toward $3.00 — roughly +47% from $2.80. Buyers look set to stay in control over this stretch.
Expect ELTX to range from $2.82 to $6.51 through 2028. The $4.11 average target implies a +47% move from current prices. That is 0% versus the projected 2027 average. Momentum favours further upside here.
The ELTX price prediction for 2029 points to an average of $4.05 (low $2.63, high $6.73) — a potential gain of +45% on today's $2.80. Buyers look set to stay in control over this stretch.
In 2030, ELTX is projected to trade between $2.53 and $7.06, averaging $4.08 — a potential gain of +46% from today's $2.80. That is up +1% on the projected 2029 average. Momentum favours further upside here.
Elicio Therapeutics, Inc.'s 2031 outlook centres on $3.99, within a $2.37 to $7.16 range. That is -2% versus the projected 2030 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ELTX could reach as high as $9.48, with a base case around $5.13 and support toward $2.91 — roughly +83% from $2.80. Momentum favours further upside here.
Expect ELTX to range from $3.56 to $12.38 through 2033. The $6.51 average target implies a +133% move from current prices. That is up +27% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ELTX price prediction for 2034 points to an average of $7.23 (low $3.79, high $14.09) — a potential gain of +158% on today's $2.80. Momentum favours further upside here.
In 2035, ELTX is projected to trade between $3.82 and $15.08, averaging $7.56 — a potential gain of +170% from today's $2.80. That is up +5% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Elicio Therapeutics, Inc.'s 2040 outlook centres on $12.70, within a $5.72 to $27.86 range. That is up +68% on the projected 2035 average. That marks a +354% change versus current levels. Momentum favours further upside here.
By 2050, ELTX could reach as high as $33.90, with a base case around $14.74 and support toward $6.63 — roughly +426% from $2.80. Buyers look set to stay in control over this stretch.
Investing $1,000 in ELTX today (≈ 357.142857 ELTX) could be worth
$5,264.42
+$4,264.42 (+426%) by 2050 · US Dollar
Based on the average projected ELTX price of $14.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ELTXwould be worth at today's price.
$1,000 invested in ELTX on Jul 31, 2025 (≈ 101.936795 ELTX) would be worth
$285.42
-$714.58 (-71.5%) today · 0.29× · US Dollar
Based on a ELTX entry price of $9.81 vs. today's $2.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3 | $933.33 | -6.7% |
| 1 month ago | $5.14 | $544.75 | -45.5% |
| 3 months ago | $10.75 | $260.47 | -74.0% |
| 6 months ago | $8.1 | $345.68 | -65.4% |
| 1 year ago | $9.81 | $285.42 | -71.5% |
| All time (5.0y) ago | $112.1 | $24.98 | -97.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ELTX forecast.
Our base-case forecast reaches $5.60 around 2033.
Implied market cap at $5.60: $147.08M
The multi-year forecast moves from a neutral start in 2026 to a sustained bullish trajectory from 2027 onward. By 2030, the average price is projected at $4.09 with a 46.1% ROI, and by 2040 the average reaches $12.68 with a 352.8% ROI. The 2050 horizon shows an average of $14.76 and a 427.2% ROI.
2032 and 2033 demonstrate notable acceleration, with 2032 averaging $5.13 (83.2% ROI) and 2033 averaging $6.53 (133.1% ROI). These figures reflect the asset’s potential upside alongside substantial uncertainty inherent to clinical-stage biotechnology. While the forecast paints a bullish longer-term path, outcomes depend on clinical results and development milestones.
Tap a question to reveal the answer.
2030 avg $4.09 with min $2.54 and max $7.08; ROI 46.1%; sentiment BULLISH.
The 2026 forecast shows avg $2.80 with 0% ROI; from 2027 onward the forecast is BULLISH with averages up to $14.76 by 2050 and ROI up to 427.2%. These are estimates, not guarantees.
Yes. The 2033 forecast shows a max of $12.40 and an average of $6.53 with ROI 133.1% and a BULLISH sentiment.
Current price is $2.80 and market capitalization is $73.54M.
Sentiment is NEUTRAL; RSI(14) is 30. SMA(50) is $6.41 and SMA(200) is $8.83. Support is $2.80 and resistance is $5.14. The 30-day range is $1.76–$4.45 and annualized volatility is 100%.
Elicio Therapeutics, Inc. Community Discussion
0Share your Elicio Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.